Filing Details

Accession Number:
0001209191-15-059967
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-07 17:11:46
Reporting Period:
2015-07-02
Filing Date:
2015-07-07
Accepted Time:
2015-07-07 17:11:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610876 Jeffrey Chodakewitz C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp Gmda, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-02 2,291 $73.51 102,853 No 4 M Direct
Common Stock Disposition 2015-07-02 394 $126.69 102,459 No 4 S Direct
Common Stock Disposition 2015-07-02 500 $128.12 101,959 No 4 S Direct
Common Stock Disposition 2015-07-02 100 $129.54 101,859 No 4 S Direct
Common Stock Disposition 2015-07-02 1,297 $130.63 100,562 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-07-02 2,291 $0.00 2,291 $73.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,253 2024-01-01 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $126.69 (range $126.10 to $126.97).
  3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $128.12 (range $127.81 to $128.47).
  5. Open market sales reported on this line occurred at a weighted average price of $130.63 (range $130.58 to $130.68).
  6. The option vests in 16 quarterly installments from 01/02/2014.